Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
0.588
+0.001 (0.17%)
Jan 21, 2025, 4:00 PM EST - Market closed
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for LCTX stock have an average target of 4.80, with a low estimate of 2.00 and a high estimate of 9.00. The average target predicts an increase of 715.77% from the current stock price of 0.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for LCTX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $5 → $3 | Strong Buy | Maintains | $5 → $3 | +409.86% | Jan 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $2 | Strong Buy | Maintains | $2 | +239.90% | Jan 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $9 | Strong Buy | Maintains | $7 → $9 | +1,429.57% | Dec 4, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $3 → $2 | Strong Buy | Maintains | $3 → $2 | +239.90% | Nov 20, 2024 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +409.86% | Nov 18, 2024 |
Financial Forecast
Revenue This Year
8.42M
from 8.95M
Decreased by -5.88%
Revenue Next Year
11.88M
from 8.42M
Increased by 41.15%
EPS This Year
-0.13
from -0.12
EPS Next Year
-0.15
from -0.13
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 10.9M | 26.7M | 38.0M | |||
| Avg | 8.4M | 11.9M | 16.1M | |||
| Low | 7.3M | 3.3M | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 22.2% | 216.8% | 219.9% | |||
| Avg | -5.9% | 41.1% | 35.7% | |||
| Low | -18.2% | -61.1% | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.01 | -0.07 | -0.03 | |||
| Avg | -0.13 | -0.15 | -0.16 | |||
| Low | -0.18 | -0.24 | -0.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.